DUPILUMAB

Brand name:

• Dupixent®

Pharmaceutical company:

SANOFI-AVENTIS AUSTRALIA PTY LTD

Condition/indication:
(therapeutic use)

• Chronic severe atopic dermatitis;
• Uncontrolled severe asthma.

PBAC Submission type:

Change to PBS listing (–)

Comment:

--

Public Summary Document:

PBAC Public Summary Documents – November 2022

Related medicines:

--

Submission received for:

November 2022 PBAC meeting

Opportunity for consumer comment:

Open 27/07/2022 and close 21/09/2022 (see PBS Website)

PBAC meeting:

Held on 02/11/2022

PBAC outcome published:

Recommended (see PBAC Outcomes)

Notice of intent submitted:

10/04/2025

5Lodgement of required documentation:

22/04/2025

Acceptance of complete documentation:

Under consideration

6Agreement to listing arrangements:

Has not yet commenced

7Government processes:

Has not yet commenced

8Medicine listed on the PBS:

Has not yet occurred

---